Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18366662 | 0.82 | RIPK1 (0.42) | GAA | |
| SCHEMBL22887611 | 0.75 | DRD2 (0.35) | NFKB1NFKB2RELACTSKSUV39H2 | |
| SCHEMBL31696419 | 0.73 | GPR119 (0.35) | CKS1BSKP1SKP2KDM4D | |
| SCHEMBL31696434 | 0.71 | — | — | |
| SCHEMBL30892162 | 0.71 | GAA (0.42) | GAANFKB1NFKB2RELACTSK | |
| SCHEMBL31696397 | 0.71 | — | — | |
| SCHEMBL26026951 | 0.71 | GRM5 (0.36) | KMT2A | |
| SCHEMBL31696554 | 0.71 | RIPK1 (0.35) | — | |
| SCHEMBL18366657 | 0.70 | RIPK1 (0.42) | GAA | |
| SCHEMBL30926332 | 0.69 | GAA (0.36) | GAANFKB1NFKB2RELAKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | GAA 941/4885NFKB1 3463/4885NFKB2 3140/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | GAA 3225/4885NFKB1 3765/4885NFKB2 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.